@jiajennyliu
Early Phase Trials Medical Oncologist / Translational Researcher 👩🏻⚕️ @kinghorncancer St Vincent’s Hospital Sydney Associate Professor @UNSW. MOGA Exec. #PrecisionMedicine #drugdevelopment Passionate about mentorship ❤️ / wellness 🤸🏻♀️/ communication 🧬📣
An incredible presentation - thank you @drcamidge.bsky.social for your courage, insight and inspiration as a patient and clinician who has walked both sides of the cancer journey
Must watch ⬇️
m.youtube.com/watch?v=cnh5...
🔗 Apply here: moga.org.au/2026-acord-wor…
#ACORD2026 #ClinicalTrials #OncologyResearch #AsiaPacific @theaacr.bsky.social @oncoalert.bsky.social @oncodaily.bsky.social
📢 ACORD 2026 applications are OPEN
6-day immersive workshop helping early-career clinical researchers turn strong ideas into high-quality, fundable clinical trials with expert mentorship!
🌏 Strongly encouraging applications from across the Asia-Pacific
📅 Sept 2026 Sydney
2011 PhD student → 2025 drug development oncologist.
A long road, a lot of growth, and so many people to thank along the way.
Grateful to be promoted to Conjoint Associate Professor at @UNSW.
Excited for the next stage of global collaboration in early phase trials 🧬🧫🔬👩🏻⚕️
Congrats @RashaCosman on late breaking oral presentation, showcasing safety and MOA of novel in vivo CAR targeting TROP2 expressing tumors #SITC25 @NECTANSW - led trial from 🇦🇺 👏.
This technology will expand access to solid tumor cell therapy 🌟
One of the Most Insightful Sessions for Me at ESMO 2025 - Jia (Jenny) Liu
@jiajennyliu.bsky.social @myesmo.bsky.social
oncodaily.com/voices/jia-j...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMO25 #ESMO2025
🌏 Full circle moment — from developing my first trial protocol as a trainee at #ACORD19 to now being elected Deputy Convenor (2026) and incoming Chair of the 🇦🇺/APAC Oncology Research Workshop.
🙏 opportunity to train the next gen of clinical trialists
shorturl.at/RN44X
Insights on ADC Toxicity Strategies in Drug Development from ESMO25 - Jia (Jenny) Liu
@jiajennyliu.bsky.social @ptarantinomd.bsky.social @myesmo.bsky.social
oncodaily.com/voices/adc-t...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMO25 #ESMO2025
Co-Chairing the Inaugural Tumour-Agnostic Track at ESMO25 - Jia (Jenny) Liu
@jiajennyliu.bsky.social @myesmo.bsky.social
oncodaily.com/voices/jia-l...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMO25 #ESMO2025
D-7 until #ESMO25! 👋🇩🇪
Excited to be part of first ever tumor-agnostic scientific track with @viveksubbiah.bsky.social @JulianaRBeale #NiamhColeman
Don’t miss these educational sessions! ⬇️ @myesmo.bsky.social
EOI for the @MOGA_ORG Mentorship Program #NOMP25 closing soon!
We invite all 🇦🇺 med onc consultants and trainees to sign up. Benefits include networking outside your workplace, support to address career navigation, wellbeing and burnout.
🔗: shorturl.at/pS3Fg
💡 Dendrimer may offer a non-antibody alternative to improve cytotoxic payload delivery—thanks to EPR effect in tumors
Could this be a platform for future payloads?
👏 co-authors @oncocook.bsky.social @anthonymjoshua.bsky.social #Starpharma, #ECMC + #NECTANSW 🇦🇺🇬🇧
🙏 patients, families, site teams
Efficacy:
DCR: 56.4% (mono 3wkly), 71.4% (mono 2wkly), 81.3% (combo with 5FU)
⏳ mPFS: 2.1, 6.0, 4.2 mo respectively
🔁 Durable benefit:
• PROC: 7 pts ≥6mo (3 >12mo)
• CRC: 12 pts ≥6mo (4 >12mo)
PFS for CRC and ovarian cancer below
Safety:
✅ 89.7% of TRAEs were mild/moderate
⚠️ Neutropenia = key DLT + most common grade 3/4 event
❗️Severe GI AEs were rare (G3 diarrhea & vomiting in 0.9%, nausea in 1.8%)
🙅♀️ No cholinergic symptoms observed
📌 Study snapshot:
🔬 First-in-human, multi-site (🇦🇺+🇬🇧)
👥 114 patients, Tumors: CRC, ovarian, pancreatic, breast, median 4 prior lines therapy
💉 12.5 mg/m² RP2D mono and combo 5FU
Our early-phase trial of DEP-SN38, a poly-lysine dendrimer–conjugated SN38 platform, is now published @ascocancer.bsky.social #JCO @oncocook.bsky.social
💡As TOP1I ADC programs rise, there's growing interest in better payload delivery—and not just through antibodies.
Can dendrimers assist? ⬇️🧵
One week until the inaugural #ESMOTATAsia25 🤩
I'm looking forward to joining global drug development experts in🍜🇭🇰
+ sharing insights on dose optimisation of novel combinations
🗓️ Saturday 19 July 2pm.
@myesmo.bsky.social @herbloongmd.bsky.social @anmwongnz.bsky.social
Live Webinar @cmri_aus
Unlocking Proteomics for Smarter ADC Development
🗓 Thurs 26 June 2025 | 4–5:15 PM AEST
Join us on mass spec-based proteomics to accelerate and refine ADC development.
events.teams.microsoft.com/event/271eed...
Come work with us St Vincent's Private Hospital Sydney! 🏥🧬🩺
Position for oncology / hematology career medical officer now open:
svha.wd3.myworkdayjobs.com/en-GB/SVHA_S...
Visual Abstract. Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Atezolizumab did not improve clinical outcomes in patients with locally advanced squamous cell carcinoma of the head and neck at high risk of disease progression after multimodal definitive treatment.
https://ja.ma/4jVjthY
AACR12 vs AACR25 - Jia Liu
@jiajennyliu.bsky.social @theaacr.bsky.social @kinghorncancer.bsky.social
oncodaily.com/blog/jia-liu...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #AACR25 #AACR12
Drs. Michael Cecchini and @jiajennyliu.bsky.social co-chair an exciting symposium #AACR25 on new antibody drug conjugate (ADC) and immuno-oncology focused approaches to treating #cancer.
@theaacr.bsky.social
A powerful conclusion to the opening ceremony of #AACR25 - cancer research saves lives 💚 @theaacr.bsky.social
Incredible #AACR25 #WICR leadership workshop on now on building resilience in science 🔬🧬💃
loving the networking and open discussions + 🥗🥪🍪
@theaacr.bsky.social @hfpconsulting.bsky.social
Link to preprint for further details ➡️ arxiv.org/abs/2409.15663
Great workshop and talk #YingYuan
@mdanderson.bsky.social @fda.gov
on 🔧 backfill strategies in early phase trials including novel BARD covariate-adaptive randomisation strategies allowing dose escalation, backfill and randomisation data to ⏫ efficiency of 🧬 trials #ProjectOptimus #AACR25
Yes it’s amazing app, helpful if you have multiple long haul flights which is frequently my problem working in drug development from 🇦🇺! You get a trial and if you like it worth buying the annual subscription
It’s that time of the year again… Getting ready to 🦹♀️timeshift - heading to @AACR #AACR25 and looking forward to connecting with 🌍 colleagues very soon!
Sacituzumab + Pembro in ASCENT04 improves Progression Free Survival in Patients With Previously Untreated PD-L1 Metastatic Triple-Negative Breast Cancer #bcsm www.gilead.com/news/news-de... @oncoalert.bsky.social
